Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients

Rosalie M. Luiten, Esther W M Kueter, Walter Mooi, Maarten P W Gallee, Elaine M. Rankin, Winald R. Gerritsen, Shirley M. Clift, Willem J. Nooijen, Pauline Weder, Willeke F. Van De Kasteele, Johan Sein, Paul C M Van Den Berk, Omgo E. Nieweg, Anton M. Berns, Hergen Spits, Gijsbert C. de Gast

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Patients and Methods: Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays. Results: The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-γ on specific antigenic stimulation. Conclusion: We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation.

Original languageEnglish (US)
Pages (from-to)8978-8991
Number of pages14
JournalJournal of Clinical Oncology
Volume23
Issue number35
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Vitiligo
Granulocyte-Macrophage Colony-Stimulating Factor
Melanoma
Vaccination
Neoplasms
T-Lymphocytes
Disease-Free Survival
Melanoma-Specific Antigens
Cancer Vaccines
Monophenol Monooxygenase
Melanocytes
Differentiation Antigens
HLA Antigens
Interferons
Vaccines
Phenotype
Skin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Luiten, R. M., Kueter, E. W. M., Mooi, W., Gallee, M. P. W., Rankin, E. M., Gerritsen, W. R., ... de Gast, G. C. (2005). Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Journal of Clinical Oncology, 23(35), 8978-8991. https://doi.org/10.1200/JCO.2005.01.6816

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. / Luiten, Rosalie M.; Kueter, Esther W M; Mooi, Walter; Gallee, Maarten P W; Rankin, Elaine M.; Gerritsen, Winald R.; Clift, Shirley M.; Nooijen, Willem J.; Weder, Pauline; Van De Kasteele, Willeke F.; Sein, Johan; Van Den Berk, Paul C M; Nieweg, Omgo E.; Berns, Anton M.; Spits, Hergen; de Gast, Gijsbert C.

In: Journal of Clinical Oncology, Vol. 23, No. 35, 2005, p. 8978-8991.

Research output: Contribution to journalArticle

Luiten, RM, Kueter, EWM, Mooi, W, Gallee, MPW, Rankin, EM, Gerritsen, WR, Clift, SM, Nooijen, WJ, Weder, P, Van De Kasteele, WF, Sein, J, Van Den Berk, PCM, Nieweg, OE, Berns, AM, Spits, H & de Gast, GC 2005, 'Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients', Journal of Clinical Oncology, vol. 23, no. 35, pp. 8978-8991. https://doi.org/10.1200/JCO.2005.01.6816
Luiten, Rosalie M. ; Kueter, Esther W M ; Mooi, Walter ; Gallee, Maarten P W ; Rankin, Elaine M. ; Gerritsen, Winald R. ; Clift, Shirley M. ; Nooijen, Willem J. ; Weder, Pauline ; Van De Kasteele, Willeke F. ; Sein, Johan ; Van Den Berk, Paul C M ; Nieweg, Omgo E. ; Berns, Anton M. ; Spits, Hergen ; de Gast, Gijsbert C. / Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 35. pp. 8978-8991.
@article{7cc9ca6412654f2686e6c2660ab4d8a6,
title = "Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients",
abstract = "Purpose: To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Patients and Methods: Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88{\%}), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays. Results: The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-γ on specific antigenic stimulation. Conclusion: We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation.",
author = "Luiten, {Rosalie M.} and Kueter, {Esther W M} and Walter Mooi and Gallee, {Maarten P W} and Rankin, {Elaine M.} and Gerritsen, {Winald R.} and Clift, {Shirley M.} and Nooijen, {Willem J.} and Pauline Weder and {Van De Kasteele}, {Willeke F.} and Johan Sein and {Van Den Berk}, {Paul C M} and Nieweg, {Omgo E.} and Berns, {Anton M.} and Hergen Spits and {de Gast}, {Gijsbert C.}",
year = "2005",
doi = "10.1200/JCO.2005.01.6816",
language = "English (US)",
volume = "23",
pages = "8978--8991",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

TY - JOUR

T1 - Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients

AU - Luiten, Rosalie M.

AU - Kueter, Esther W M

AU - Mooi, Walter

AU - Gallee, Maarten P W

AU - Rankin, Elaine M.

AU - Gerritsen, Winald R.

AU - Clift, Shirley M.

AU - Nooijen, Willem J.

AU - Weder, Pauline

AU - Van De Kasteele, Willeke F.

AU - Sein, Johan

AU - Van Den Berk, Paul C M

AU - Nieweg, Omgo E.

AU - Berns, Anton M.

AU - Spits, Hergen

AU - de Gast, Gijsbert C.

PY - 2005

Y1 - 2005

N2 - Purpose: To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Patients and Methods: Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays. Results: The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-γ on specific antigenic stimulation. Conclusion: We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation.

AB - Purpose: To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Patients and Methods: Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays. Results: The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-γ on specific antigenic stimulation. Conclusion: We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation.

UR - http://www.scopus.com/inward/record.url?scp=33644813226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644813226&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.01.6816

DO - 10.1200/JCO.2005.01.6816

M3 - Article

VL - 23

SP - 8978

EP - 8991

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -